MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/17588359241247019

Медицинская библиотека · Therapeutic advances in medical oncology · 2024

The concomitant use of the renin-angiotensin system inhibitors and survival outcomes of patients with pancreatic adenocarcinoma: an analysis from a tertiary center.

Tseng Kuan-Yu, Hsu Chiann-Yi, Shih Yu-Hsuan, Lin Hsin-Chen, Li You-Cheng, Jerry Teng Chieh-Lin, Chou Cheng-Wei

СтатьяПеревод в очереди

Аннотация

BACKGROUND

The limited efficacy of chemotherapy in improving survival in pancreatic ductal adenocarcinoma (PDAC) necessitates the exploration of novel strategies to overcome treatment resistance.

OBJECTIVES

This study aimed to investigate the impact of combining renin-angiotensin system (RAS) blockers with chemotherapy on survival outcomes in patients with PDAC.

DESIGN

Patients with PDAC were enrolled in the retrospective study.

METHODS

We analyzed patients with PDAC (n = 384) at our institution between 2014 and 2021. Survival outcomes, including event-free survival (EFS) and overall survival (OS), were analyzed according to the concomitant use of RAS blockers.

RESULTS

Among the 384 patients in the study, 70 (18.2%) concomitantly received angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). Patients in the ACEI/ARB group, characterized by older age and more comorbidities, displayed a significantly superior 12-month EFS rate (22.86% versus 13.69%, p = 0.008) compared to the non-ACEI/ARB group, while OS remained similar between the groups. In the multivariate analysis, the use of ACEI/ARB was associated with better 12-month EFS (hazards ratio = 0.71, 95% confidence interval: 0.52-0.96; p = 0.024). Poor performance, advanced disease status, and higher CA19-9 levels were associated with poor survival outcomes.

CONCLUSION

Concomitant use of ACEIs/ARBs in patients with pancreatic cancer resulted in significantly better 12-month EFS. Age, performance status, disease status, and higher CA19-9 levels were independent predictors of survival. The combination strategy might provide better treatment outcomes in patients with PDAC.

Для цитирования: Tseng Kuan-Yu, Hsu Chiann-Yi, Shih Yu-Hsuan, Lin Hsin-Chen, Li You-Cheng, Jerry Teng Chieh-Lin, Chou Cheng-Wei. The concomitant use of the renin-angiotensin system inhibitors and survival outcomes of patients with pancreatic adenocarcinoma: an analysis from a tertiary center.. Therapeutic advances in medical oncology. 2024. DOI: 10.1177/17588359241247019.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.